# FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression

> **NCT02325739** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 172 (actual)

## Conditions studied

- Hepatocellular Carcinoma (HCC)
- Solid Malignancies

## Interventions

- **DRUG:** FGF401
- **BIOLOGICAL:** PDR001

## Key facts

- **NCT ID:** NCT02325739
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-29
- **Primary completion:** 2019-05-30
- **Final completion:** 2019-05-30
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2024-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02325739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02325739, "FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT02325739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*